Drug Trial Radar · NCT06873334
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
May 27, 2025
Primary completion
May 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Skyhawk Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.
Conditions
- Huntington Disease
- Huntingtons Disease
Interventions
SKY-0515Drug
Study Drug Name (INN): SKY-0515 Type: Drug (small molecule) Dosage Level(s): Low, mid, high Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 12 months Use: Experimental Sourcing: SKY-0515 will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements.
SKY-0515 PlaceboDrug
Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 12 months Use: Experimental Sourcing: SKY-0515 placebo will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in blood mHTT protein levelsTime frame: 12 months
- Changes in brain volume measured through MRITime frame: 12 months
- Changes in UHDRSTime frame: 12 months
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
John Hunter Hospital
New Lambton Heights, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
The University of Queensland
Herston, Queensland, Australia
Flinders Medical Centre
Adelaide, South Australia, Australia
Launceston General Hospital
Launceston, Tasmania, Australia
Calvary Health Care Bethlehem
Caulfield South, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
The Perron Institute for Neurology and Translational Science (Perron Institute)
Nedlands, Western Australia, Australia
Huntington's Disease Association
Auckland, New Zealand
Auckland City Hospital
Auckland, New Zealand
Christchurch Neurology Trials Limited
Christchurch, New Zealand
Wellington Hospital
Wellington, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.